Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States

HIV Clinical Trials

Volumn 13, Issue 1, 2012, Pages 11-22

  Cragin, Lael ^a   Pan, Feng ^a   Peng, Siyang ^a   Zenilman, Jonathan ^b,c   Green, Julia ^a   Doucet, Cynthia ^d   Chalfin, Donald ^d   De Lissovoy, Greg ^a,e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^d ABBOTT DIAGNOSTICS   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cost effectiveness; HIV infection; screening; testing

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIGEN P24;

3RD GENERATION HUMAN IMMUNODEFICIENCY VIRUS TEST; 4TH GENERATION HUMAN IMMUNODEFICIENCY VIRUS TEST; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE TRANSMISSION; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOASSAY; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED STATES; VIRUS DETECTION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84858195640     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1301-11     Document Type: Article

References (46)

1. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiag-nosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619-624.
2. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447-1450. (Pubitemid 43948252)
3. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17; quiz CE11-14.
4. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med. 2010;170(1):66-74.
5. Quinn TC. Acute primary HIV infection. JAMA. 1997;278(1):58-62. (Pubitemid 27274518)
6. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010; 202(Suppl 2):S270-S277
7. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871-1879.
8. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195(7):951-959. (Pubitemid 46452099)
9. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687-693.
10. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS. 2007;21(12):1625-1629. (Pubitemid 47075484)
11. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403-1409. (Pubitemid 40563350)
12. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep. 2001;50(RR-19):63-85; quiz CE61-19a62-CE66-19a62.
13. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50(RR-19):1-57; quiz CE51-19a51-CE56-19a51.
14. Pandori MW, Hackett J Jr, Louie B, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol. 2009;47(8):2639-2642.
15. Westreich DJ, Hudgens MG, Fiscus SA, Pilcher CD. Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests. J Clin Microbiol. 2008;46(5):1785-1792. (Pubitemid 351657230)
16. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352(18):1873-1883. (Pubitemid 40627813)
17. Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797-806. (Pubitemid 351650333)
18. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570-585. (Pubitemid 40204670)
19. HIV prevalence estimates-United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(39):1073-1076.
20. Centers for Disease Control and Prevention. HIV/AIDS s urveillance report, 2007. Vol 19. http://www.cdc.gov/hiv/topics/surveillance/resources/ reports/. Accessed N ovember 11, 2010.
21. White DA, Scribner AN, Schulden JD, Branson BM, H effelfinger JD. Results of a rapid HIV screening and diagnostic testing program in an urban emergency department. Ann Emerg Med. 2009;54(1):56-64.
22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 21, 2010.
23. Gras L, Jurriaans S, Bakker M, et al. Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One. 2009;4(10):e7365.
24. Kared H, Lelievre JD, Donkova-Petrini V, et al. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS. 2008;22(18):2451-2460.
25. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-1363.
26. Breaux K, Gadde S, Graviss EA, Rodriguez-Barradas MC. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort. AIDS Care. 2010;22(7):886-894.
27. Koblin BA, van Benthem BH, Buchbinder SP, et al. Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995. Am J Epidemiol. 1999;150(10):1026-1030. (Pubitemid 29531938)
28. Association of Public Health Laboratories. Member survey of HIV assay use. HIV: 2009 diagnostic survey. http://www.aphl.org/aphlprograms/infectious/ hiv/Documents/HIV-2009-Survey.pdf. Accessed November 11, 2010.
29. Abbott Laboratories. ARCHITECT HIV Ag/Ab Combo Reagent prescribing information. Wiesbaden, Germany; 2009.
30. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5):308-320. (Pubitemid 351480523)
31. Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR. Cost-effectiveness of MRI compared to mammogra-phy for breast cancer screening in a high risk population. BMC Health Serv Res. 2009;9:9.
32. Tosteson AN, Stout NK, Fryback DG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008;148(1):1-10. (Pubitemid 351664941)
33. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778-789.
34. Prejean J, Song R, Hernandez A, et al. Estimated HIV Incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
35. Hutchinson AB, Patel P, Sansom SL, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV a ntibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7(9):e1000342.
36. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13(10):716-717. (Pubitemid 28473801)
37. Centers for Disease Control and Prevention. HIV testing in the US. CDC Vitalsigns. http://www.cdc.gov/VitalSigns/pdf/2010-11-30-vitalsigns.pdf. Accessed December 21, 2010.
38. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24(11):1043-1053. (Pubitemid 44683362)
39. Simpson KN, Strassburger A, Jones WJ, Dietz B, Raja-gopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27(2):159-165.
40. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the united states. Med Care. 2006;44(11):990-997. (Pubitemid 44674030)
41. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. Science. 1998;280(5371):1889-1894.
42. Kamb ML, Fishbein M, Douglas JM, Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280(13):1161-1167. (Pubitemid 28457806)
43. Denison JA, O'Reilly KR, Schmid GP, Kennedy CE, Sweat MD. HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav. 2008;12(3):363-373.
44. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-929. (Pubitemid 30177052)
45. Centers for Medicare and Medicaid Services. Clinical Diagnostic Laboratory Fee Schedule. National average fee. https://www.cms.gov/ ClinicalLabFeeSched/. Accessed December 21, 2010.
46. Centers for Medicare and Medicaid Services. Physician Fee Schedule, National Payment Amount File CY 2010. https://www.cms.gov/PhysicianFeeSched/. Accessed December 21, 2010.